Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
PHASE2
This phase II trial compares the effect of usual radiation therapy with cis...
A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)
PHASE3
The primary objective of the study was to demonstrate superior efficacy of ...
Status
Terminated
Location
The University of Alabama at Birmingham - Hazelrig-Salter Radiation Oncology Center (HSROC)